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Abstract
Chimpanzees (Pan troglodytes) have contributed to diverse fields of biomedical research due to their close genetic relationship to
humans and in many instances due to the lack of any other animal model. This review focuses on the contributions of the
chimpanzee model to research on hepatitis viruses where chimpanzees represented the only animal model (hepatitis B and C) or
the most appropriate animal model (hepatitis A). Research with chimpanzees led to the development of vaccines for HAV and HBV
that are used worldwide to protect hundreds of millions from these diseases and, where fully implemented, have provided
immunity for entire generations. More recently, chimpanzee research was instrumental in the development of curative therapies
for hepatitis C virus infections. Over a span of 40 years, this research would identify the causative agent of NonA,NonB hepatitis,
validate the molecular tools for drug discovery, and provide safety and efficacy data on the therapies that now provide a rapid and
complete cure of HCV chronic infections. Several cocktails of antivirals are FDA approved that eliminate the virus following 12
weeks of once-per-day oral therapy. This represents the first cure of a chronic viral disease and, once broadly implemented, will
dramatically reduce the occurrence of cirrhosis and liver cancer. The recent contributions of chimpanzees to our current
understanding of T cell immunity for HCV, development of novel therapeutics for HBV, and the biology of HAV are reviewed.
Finally, a perspective is provided on the events leading to the cessation of the use of chimpanzees in research and the future of the
chimpanzees previously used to bring about these amazing breakthroughs in human healthcare.
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Introduction to Viral Hepatitis
Many viral infections can involve some inflammation of the liver
or hepatitis. Those that have a specific tropism for the liver are
designated as hepatitis A-E and share no virological relationship
other than their tropism for the liver. The alphabetical designa-
tion of these viruses stems from the development of diagnostic
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assays capable of discrimination of the various infections that
clinically manifest as hepatitis. The members of this group most
devastating to humans are simply known as hepatitis A, B, and
C. Chimpanzee (Pan troglodytes) models have been used exten-
sively for research on vaccines and therapies for these viruses
(Table 1). Hepatitis B (HBV) and HCV have a predilection for
causing persistent infections that, over decades, induce serious
liver diseases including cirrhosis and liver cancer. HAV most fre-
quently causes an acute resolving infection that is most severe
in those exposed after childhood and can progress to life-
threatening fulminant hepatitis. A brief description of the
viruses reviewed in this chapter is provided below with refer-
ences for more extensive reviews.
The prevalence of HCV infection is 3% worldwide with an esti-
mated 170 million people persistently infected. The U.S. adult
population (~40–60 years of age) has a prevalence of approxi-
mately 4%. The disease is typically asymptomatic or mild for sev-
eral decades; however, up to 20% of infected individuals
eventually develop cirrhosis, and these individuals are at risk for
progression to hepatocellular carcinoma (Alter and Seeff 2000;
Thomas and Seeff 2005). End-stage liver disease due to HCV infec-
tion is the leading cause of liver transplantation in the United
States, and HCV-associated liver cancer is now the most rapidly
increasing cause of death due to cancer in the United States with
an estimated 750,000 deaths annually. HCV liver disease is also a
leading cause of morbidity and mortality in individuals co-
infected with HIV whose HIV infection is under control with anti-
viral therapy, but who will experience more rapid progression of
liver disease. HCV is a member of the Flaviviridae family within
the Hepacivirus genus. HCV is a single-stranded, positive-sense,
RNA virus with seven genotypes that display an exceptionally
high genetic diversity (Simmonds et al. 2017; Smith et al. 2016).
The genome contains a single open reading frame that encodes a
polyprotein that is processed into 10 viral proteins by host and
viral proteases (reviewed in Bartenschlager et al. 2013; Bukh 2016;
Lindenbach and Rice 2005; Scheel and Rice 2013; Tellinghuisen
et al. 2007). The proteins of greatest importance to antiviral ther-
apy are NS3, NS5A, and NS5B (Bukh 2016; Gotte and Feld 2016).
NS3 is the serine protease, which cleaves the nonstructural pro-
teins into functional units and also contains the RNA helicase
domain. NS5A is a unique, multi-domain, zinc-finger protein that
has RNA binding activity and plays an essential role in viral
assembly and replication (Nakamoto et al. 2014; Ross-Thriepland
and Harris 2015). NS5B is the viral RNA-dependent RNA polymer-
ase. In addition, the 5′ noncoding region contains an internal ribo-
some entry site that initiates translation and two binding sites for
the liver-specific microRNA-122 that are essential for replication
(Jangra et al. 2010; Jopling et al. 2008; Masaki et al. 2015) and have
been targeted for antiviral therapy (Lanford et al. 2010). Currently,
no vaccine is available for HCV, but a great deal of our under-
standing of the immune response to HCV comes from vaccine
studies in chimpanzees, as is discussed later in this review.
Chronic HBV infection impacts over 250 million individuals
and progresses to cirrhosis and liver cancer over decades
(Chisari et al. 2010; Liang 2009). Annual deaths due to HBV-
associated hepatocellular carcinoma are estimated at nearly
786,000 per year. Two vaccines for HBV were developed through
research in chimpanzees. The initial vaccine was purified from
the blood of infected individuals and inactivated. The efficacy as
well as concerns over residual infectivity of this vaccine could
only be addressed in the chimpanzee. The current vaccine for
HBV is produced in yeast and contains the small surface protein
designated HBV surface antigen (HBsAg). This was among the
first recombinant DNA products used in man and was used for
immunization of adults and infants. Recombinant DNA products
were new at the time, and again concerns over efficacy and
safety could only be addressed in the chimpanzee. This vaccine
provides lifelong immunity and has provided immunity for entire
generations where fully implemented. Although antivirals are
available to suppress replication and disease progression, they
must be taken for life. Curative therapies are not available, but
novel new approaches will be discussed in this review. HBV is a
member of Hepadnaviridae. The virion is partially double-stranded
DNA that is the product of reverse transcription of a greater-
than-genome-length pregenomic RNA (reviewed in Seeger and
Mason 2015). This RNA is encapsidated along with the reverse
transcriptase by a single protein, the core protein. Following
reverse transcription, the capsid particle buds through the endo-
plasmic reticulum membrane and acquires a lipid envelop that is
comprised of three HBV surface proteins that overlap due to initi-
ation at three different start codons. The vaccine is comprised of
the smallest of these proteins, HBsAg.
HAV is primarily transmitted by the fecal-oral route and is
commonly acquired in early childhood in countries with poor
sanitation. An estimated 1.4 million infections occur annually.
Delay of exposure due to moderate or high sanitation in the
absence of universal vaccination causes focal and occasionally
large epidemics with a high disease burden. Infection in adults
leads to jaundice in up to 70% of those infected with over
100,000 deaths annually. A protective vaccine is available but
has not been widely implemented in most of the world. This
vaccine is based on inactivated virus produced in tissue culture
and was developed using multiple nonhuman primate (NHP)
species, with the chimpanzee studies being crucial for approval.
Efforts to derive a recombinant or peptide-based vaccine using
the chimpanzee model were not successful. HAV is a member of
the Hepatovirus family within the Picornaviridae genus (Ehrenfeld
et al. 2010; Martin and Lemon 2006). Similar to HCV, the struc-
ture of the genome is positive-sense with a single polyprotein
that is processed into 11 proteins. The capsid is comprised of
four proteins, VP 1–4. Although conventionally classified as a
nonenveloped virus due to the characteristics of excreted virus,
recent discoveries have revealed secretion of particles in the
blood that are cloaked in host membranes (Feng et al. 2013;
Walker et al. 2015) that provide protection from neutralizing
antibodies and may facilitate spread in the liver.
Discovery and Characterization of
Transfusion-Associated NonA,NonB Hepatitis
The development of assays capable of distinguishing infections
with HBV (previously serum hepatitis) and HAV (previously infec-
tious hepatitis) led to observations of the transmission of a new
type of hepatitis in hospitals involving blood or blood products.
The agent was simply designated transfusion-associated NonA,
NonB hepatitis (NANBH) (Feinstone et al. 1975), or essentially a
Table 1 Highlights of Chimpanzee Research
• Development of HBV vaccine
• Development of HAV vaccine
• Testing of HIV vaccines
• Characterization NANBH
• Cloning of HCV
• Vaccine trials for HCV
• Development of curative therapies for HCV
• Safety testing of humanized monoclonal antibodies
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virus with no name (Table 2). The difficulty of working on this
agent cannot be overemphasized. There was no method to grow
the virus in the laboratory using cell cultures, no technique to
detect the virus, and no small-animal model that could be in-
fected with the virus. The first breakthrough would occur when
Harvey Alter, a scientist at NIH, collaborated with the Southwest
Foundation for Biomedical Research (now Texas Biomedical
Research Institute) to transmit the infection to a chimpanzee
using human donor blood known to transmit the infection (Alter
et al. 1978; Hollinger et al. 1978; Tabor et al. 1978). Since the virus
could not be detected, the proof of transmission was based on
the development of mild symptoms of hepatitis in the weeks fol-
lowing inoculation. In addition, infections were monitored by
histological changes consistent with mild inflammatory disease
in the liver and the detection by electron microscopy of membra-
nous tubules in the cytoplasm of hepatocytes (Shimizu et al.
1979). Remarkably, the properties of the virus were defined using
the chimpanzee model and conventional virological techniques,
including the size of 50 to 80nM based on filtration studies
(Bradley 1985; He et al. 1987) and the presence of a lipid envelope
based on loss infectivity after exposure to chloroform (Bradley
et al. 1983; Feinstone et al. 1983b). The chimpanzee model was
used to demonstrate that blood products were often contami-
nated with NANBH due to the use of large pools of plasma in
manufacturing. Methods to inactivate the agent in blood pro-
ducts and render them safe for use in humans were based on
infectivity studies in the chimpanzee, including UV light in the
presence of beta-propiolactone (Prince et al. 1985) and solvent-
detergent treatment (Horowitz et al. 1993; Prince et al. 1984,
1987). Long-term follow-up of chimpanzees and patients revealed
that NANBH often induced chronic or persistent infections
(Bradley et al. 1981), highlighting the need to develop methods to
detect the virus and reduced transmission.
Cloning of HCV and Validation of Molecular
Tools for HCV Drug Discovery
An intensive international effort was devoted to the isolation of
this virus with no name, which resulted in more than a few false
reports. To aid in the validation of claims of discovery, Harvey
Alter developed a coded panel of human serum with known
patient histories. The isolation of HCV finally occurred when a
team of scientists at Chiron Laboratories led by Michael
Houghton cloned a small fragment of the viral genome (Alter
and Houghton 2000; Alter et al. 1989; Choo et al. 1989). This dis-
covery quickly provided the basis of an assay to screen for anti-
bodies to HCV in human blood, making the blood supply safe,
15 years after the original description of a new hepatitis in
hospitals. The initial clone was isolated from a lambda gt11
phage expression library produced using infected chimpanzee
serum and then screened with the serum from a NANBH patient
as the source of antibody. A single clone of approximately 150
nucleotides (clone 5-1-1) was detected. The dependence of this
feat on the skill and perseverance on the part of the scientists
involved is without doubt, but the essential role of the chimpan-
zee must also be appreciated. The chimpanzee serum was pro-
vided by Dan Bradley at the CDC and had been documented to
have exceptionally high levels of virus by inoculating chimpan-
zees with highly diluted samples in a titration study. The fact
that a single clone was detected out of millions of gt11 plaques
suggests that the clone would have been missed if the viral titer
of the starting material had not been of such high level. In fact,
production of additional libraries from the same source failed to
produce a second clone of HCV (Houghton 2009). The use of the
5-1-1 clone permitted selection of overlapping clones until the
entire open reading frame of the polyprotein had been captured.
This would begin the struggles to develop an infectious clone
and culture system suitable for drug discovery.
The production of a full-length infectious clone would present
a new hurdle to be overcome only after great difficulty (Table 2).
One of greatest hurdles was identification of the true 3′ terminus
of the genome. The cloning of the 3′ terminus of HCV was ham-
pered due to the low levels of starting RNA for amplification and
the lack of a polyA tail from which to prime cDNA synthesis
(Blight and Rice 1997; Kolykhalov et al. 1996; Tanaka et al. 1995,
1996). Even after the entire sequence was available, the valida-
tion of infectious clones was not straightforward. In the absence
of a culture system, the assay to validate infectivity was the
direct inoculation of in vitro transcribed synthetic RNA into the
liver of a chimpanzee. The difficulty of this task is emphasized
by the efforts of Kolykhalov and co-workers, who inoculated 34
full-length clones into chimpanzees without identification of an
infectious clone (Kolykhalov et al. 1997). The first infectious
clones were produced by making a consensus sequence based
on multiple full-length sequences from the same starting mate-
rial (Kolykhalov et al. 1997; Yanagi et al. 1997). Subsequently,
multiple infectious clones were constructed and validated in the
chimpanzee by correcting nonconsensus residues from various
strains (Beard et al. 1999; Hong et al. 1999; Lanford et al. 2001;
Yanagi et al. 1998, 1999a); this included clones representing gen-
otypes 3 and 4 (Gottwein et al. 2010). Importantly, representa-
tives of all six major genotypes have been shown to induce
infections in chimpanzees (Bukh et al. 2010), providing character-
ized material for future studies.
Despite the development of infectious clones, no tissue cul-
ture system was available for analysis of viral replication or
drug screening. Critical studies continued in the chimpanzee to
examine the infectivity of modified clones. The essential nature
of the conserved 98 nucleotide stem loop structure at the 3′
NCR (Kolykhalov et al. 2000; Yanagi et al. 1999b), the require-
ment of p7 for infectivity (Sakai et al. 2003), and the nonessen-
tial nature of the E2 HVR1 (Forns et al. 2000) were all
demonstrated in the chimpanzee in this manner.
Perhaps the most significant development with regard to
drug discovery was the creation of replicons that lack the abil-
ity to produce infectious virus but nonetheless allow analysis
of all of the functions required for RNA replication in tissue cul-
ture (Lohmann et al. 1999). Even this breakthrough would be
limited to specific viral isolates and replication in a single
human liver cancer cell line, Huh7. Substantial adaptation
occurred in the replicon in achieving high levels of replication
(Blight et al. 2000; Lohmann et al. 2001), leading to concerns
Table 2 Milestones in HCV Research
1975 New hepatitis agent recognized, NANBH
1978 NANBH transmitted to chimpanzees
1989 HCV cloned from chimpanzee serum
1990 HCV antibody assay developed to screen donor blood
Realization of chronic infections in 3% of adults
1997 Validation of infectious clones in chimpanzees
1999 Development of HCV replicon model
2005 In vitro replication of HCV in tissue culture
2006 Transmission from culture to chimp and back to culture
2000–2014 Era of drug development
Preclinical testing for HCV antivirals in chimpanzees
2014 FDA approval of first curative cocktail for HCV
174 | Lanford et al.
that specific targets may have subtle but significant differences
between the in vitro model and virus in the liver. Nonetheless,
most drugs were either developed or perfected by iterative
modification prior to preclinical trials in chimpanzees and
eventually human trials. The NS5A region displayed the most
evident differences between viral sequences supporting repli-
cation in tissue culture and virus in the liver. Adaptive muta-
tions occurring in NS5A in the replicon resulted in clearly
attenuated replication in chimpanzees and reverted to the
wild-type sequence (Bukh et al. 2002). These findings and the
lack of a molecular assay for NS5A function caused some con-
cern in approaching NS5A as a drug target, yet high throughput
assays with drug libraries repeatedly selected hits that involved
NS5A. The isolation of the JFH1 strain (Kato et al. 2003; Wakita
et al. 2005) that permitted direct infection of cells in culture for
the first time also pointed to differences in replication in vitro
and in the liver. A derivative of the Huh7 cell line, Huh7.5
(Blight et al. 2002), was required to attain high levels of replica-
tion, and virus produced in culture was highly attenuated in
chimpanzees with low level replication and a limited duration
of viremia (Kato et al. 2008; Lindenbach et al. 2006; Prentoe
et al. 2011, 2016; Wakita et al. 2005). An infectious clone repre-
senting the genotype 1a, H77-S, was optimized by incorporation
of a series of mutations to increase production of infectious
virus following transfection of permissive cells (Yi et al. 2006).
This clone was the first to induce a chronic infection in the
chimpanzee (Yi et al. 2014). Despite the advances in molecular
biology and in vitro cultivation methods, over 40 years after
description of NANBH in the clinic, replication of isolates from
patients in tissue culture is still not possible.
The Innate Immune Response to HCV
Viral RNA is sensed by a number of host proteins, which in turn
stimulate the production of type I interferon (IFNα and IFNβ) and
type III IFN (IFNλ 1–4) through complex signaling pathways. In in-
fected hepatocytes, Toll-Like Receptor 3 (TLR3) and DExD-box heli-
case receptors (RIG-I and MDA5) recognize viral RNAs via
“pathogen-associated molecular patterns,” resulting in the activa-
tion of transcription factors including interferon regulatory factor
3 (IRF-3) and NF-κB. In addition, PKR binds dsRNA, becomes acti-
vated by phosphorylation, and contributes to the activation of NF-
κB. IRF-3 and NF-κB in conjunction with other transcription factors
induce transcription of IFNβ. A distinct subset of “interferon stimu-
lated genes” (ISGs) is also directly induced by IRF-3, while NF-κB
promotes the expression of proinflammatory cytokines. In addi-
tion to the production of IFNs by infected cells, plasmacytoid den-
dritic cells (pDCs) produce IFNα following recognition by TLR7 of
viral RNAs secreted from infected cells (Garaigorta and Chisari
2009; Takahashi et al. 2010). Type I and III IFNs interact with their
receptors to initiate the JAK-STAT signaling pathway and the pro-
duction of hundreds of ISGs, bringing about a potent antiviral
response. HCV subverts the innate immune responses by several
mechanisms. The NS3/4A protease blocks both TLR3 and RIG-I
pathways and prevents the activation of IRF-3 (Foy et al. 2003,
2005; Li et al. 2005a) and NF-κB. The TLR3 pathway is blocked by
cleavage of the adaptor protein TRIF (Li et al. 2005a; Wang et al.
2009), while the RIG-I pathway is blocked by NS3/4A cleavage of
the adapter protein MAVS (aka IPS-1, CARDIF, or VISA) (Li et al.
2005b; Meylan et al. 2005). NS5A may play multiple roles in block-
ing the response to IFNα through interactions with PKR.
Early studies with NANBH explored therapeutics with no
direct mechanism to measure efficacy except for the improve-
ment of symptoms and decrease in serum levels of the liver
enzyme ALT. In 1986, interferon-α was found to reduce ALT in
50% of NANBH patients, but most relapsed following cessation
of therapy. By 1995, ribavirin was combined with IFNα, provid-
ing a cure for up to 35% of patients, but most patients could not
tolerate the 1 year of therapy required to obtain a cure. The
mechanism by which ribavirin enhanced the activity of IFNα
was not understood, since it showed no significant activity as a
monotherapy. In 2001, the introduction of PEGylated-IFNα with
ribavirin would increase the cure rate to as high as 50% follow-
ing 1 year of therapy, but the improved therapy was still pla-
gued with multiple adverse reactions.
The complexity of the mechanism of IFNα efficacy for HCV
and the variable response rate would be explored for more than
a decade. The introduction of total genome microarrays provided
an opportunity to directly explore the molecular events in the
liver during chronic HCV infection and IFNα therapy. Studies of
hepatic gene expression during acute HCV infection in chimpan-
zees revealed a rapid innate immune response occurring days
after infection involving the induction of hundreds of ISG tran-
scripts, some of which were elevated by 100-fold or more (Bigger
et al. 2001; Su et al. 2002). The ISG response parallels the rise and
decline of viremia during acute-resolving infection, leaving no
doubt that the changes are in response to viral RNA. Chronic
HCV infection also evokes a strong ISG response within the liver
in chimpanzees (Figure 1) and humans (Bigger et al. 2001, 2004;
Lanford et al. 2006, 2007; Sarasin-Filipowicz et al. 2008; Su et al.
2002), yet this response does not impact viral persistence.
Indeed, treatment of chimpanzees chronically infected with HCV
with exogenous IFNα failed to reduce viral RNA even when intro-
duced at exceptionally high levels (Lanford et al. 2007). The ISG
response in the liver of infected chimpanzees appeared to be
maximally induced, and addition of exogenous IFNα provided no
increase in ISG expression, while ISG expression in PBMC of the
same chimpanzees was highly induced. This would be desig-
nated the Null IFN response in both chimpanzees and humans.
Chimpanzees uniformly have high ISG levels during chronic and
acute infection (Figure 1), and almost every cell expresses high
levels of ISG15 (Lanford et al. 2011). In contrast, humans appear
to be divided into two groups, high versus low ISG levels, prior to
treatment. An association between high ISG levels and lack of
response to therapy agrees with data from the chimpanzee, and
in humans this correlates with polymorphisms in IL28B region
(Ge et al. 2009; Suppiah et al. 2009; Tanaka et al. 2009).
Extrapolation of the levels of viral RNA in the liver and as-
sumptions of RNA copy number per cell suggested that <10% of
hepatocytes are infected (Bigger et al. 2004; Lanford et al. 2006,
2007). These estimates are in agreement with detection of in-
fected cells using multiphoton microscopy and in situ hybrid-
ization (Liang et al. 2009; Wieland et al. 2014). One possible
conclusion from these studies is that host responses limit the
spread of the virus in the liver by inducing an ISG response in
uninfected cells, but viral proteins subvert the antiviral activity
in infected cells, allowing persistence of the infection. The
stimulus for hepatic ISG expression in most cells is not likely
viral replication and may be the production of IFNs by nearby
pDCs (Dreux et al. 2012; Lau et al. 2008; Takahashi et al. 2010).
Experimental Vaccines for HCV Infection
Spontaneous resolution of acute HCV infection in some humans
and chimpanzees confers long-lived immunity that can sharply
reduce the risk of persistent infection upon reexposure to the
virus. This observation has provided a strong foundation for
identification of protective immune responses and development
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of protective HCV vaccines. The first test of whether chimpan-
zees with naturally acquired immunity are protected against
reinfection was undertaken approximately 25 years ago, shortly
after discovery of the virus (Farci et al. 1992; Prince et al. 1992).
Rechallenge of immune animals resulted in viremia and histo-
logic changes in the liver consistent with infection. Because rein-
fection was even observed after sequential challenge with the
same HCV strain virus (Farci et al. 1992; Prince et al. 1992), it was
concluded that immunity was absent or weak and raised con-
cerns for vaccine development. This early experience with HCV
clearly differed from HAV and HBV, where natural resolution of
infection or vaccination provided robust sterilizing immunity in
chimpanzees.
A series of insightful studies about a decade later altered
this view. Reinfection after challenge of immune chimpanzees
with HCV was confirmed (Bassett et al. 2001; Major et al. 2002).
However, peak viremia was sharply attenuated and cleared
rapidly when compared with the prolonged course of primary
infection (Bassett et al. 2001; Dahari et al. 2010; Major et al. 2002).
Protection was long-lived; some animals were challenged several
years after resolution of the first infection (Bassett et al. 2001;
Major et al. 2002). Protection also extended to HCV genotypes
Figure 1 Heat Map of Hepatic Gene Expression in HCV Chronic Chimpanzees. The 30 most highly induced genes in the liver of HCV chronically infected chimpanzees
are shown in red. The analyses involve total genome microarray analysis from 16 liver samples from HCV-infected chimpanzees in comparison to 6 uninfected chim-
panzees. The 30 genes with the greatest decrease in expression in infected liver are shown in green. The genes increased in expression are primarily ISGs as deter-
mined by comparison to uninfected animals treated with IFNα. These genes are uniformly expressed at high levels during HCV infection. The genes decreased in
expression may reflect some genes specifically regulated by IFN, but the response is variable in different chimpanzees.
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different from the one that established the first resolving infection
(Lanford et al. 2004; Prince et al. 2005). For instance, in one study,
recovery from a genotype 1 HCV infection protected animals
against persistent infection with a mixed inoculum of genotype 1,
2, 3, and 4 viruses that were up to 30% different at the amino acid
level (Lanford et al. 2004). It is important to emphasize that natu-
rally acquired protection sometimes failed (Bukh et al. 2008; Prince
et al. 2005). In one remarkable example, a chimpanzee was par-
tially or completely protected following five homologous rechal-
lenges with a genotype 1a virus and six heterologous rechallenges
with genotype 1b and 2a viruses (Bukh et al. 2008). A final chal-
lenge with the genotype 1a virus that established the initial
resolving infection resulted in persistence (Bukh et al. 2008).
Collectively, these animal studies provided a compelling
rationale for development of a pan-genotypic HCV vaccine and
suggested that protection does not require sterilizing immunity.
Prevention of persistence is considered a more realistic objective
for vaccination given the largely asymptomatic nature of acute
hepatitis C, an apparent absence of latent HCV genomes that
could cause a relapsing infection, and the capacity to cure any
breakthrough infections with direct acting antivirals (DAA).
Mechanisms of Protective Immunity
Precisely how natural resolution of HCV infection provides protec-
tion from persistence is still not fully understood. Chimpanzee
studies have provided evidence that T cells and antibodies con-
tribute to control of HCV replication (Dahari et al. 2010).
T Cells and Protective Immunity
Early chimpanzee studies demonstrated that successful control
of virus replication occurs 2 to 3 months after HCV challenge.
The sharp reduction in viremia was kinetically associated with
upregulation of genes associated with an adaptive immune
response like IFN-γ gene expression in liver (Bigger et al. 2004; Su
et al. 2002) and expansion of HCV-specific T cells in blood and
liver (Cooper et al. 1999; Thimme et al. 2002). Importantly, reex-
posure of animals to HCV resulted in accelerated IFN-γ and T cell
responses that were associated with rapid clearance of infection
(Bassett et al. 2001; Grakoui et al. 2003; Major et al. 2002;
Nascimbeni et al. 2003; Shoukry et al. 2003). These findings are
similar to those from humans with acute hepatitis C (Klenerman
and Thimme 2012). Depletion of CD4+ or CD8+ T cells from
chimpanzees with naturally acquired immunity immediately
before rechallenge with HCV provided additional direct evidence
of their contribution to infection control (Grakoui et al. 2003;
Shoukry et al. 2003). Antibody-mediated depletion of CD4+
helper T cells resulted in persistent HCV infection instead of
rapid resolution (Grakoui et al. 2003). Memory CD8+ T cells in
these animals selected for escape mutations in class I epitopes
and lost antiviral effector functions. Depletion of CD8+ cytotoxic
T cells in a second set of animals resulted in prolonged virus rep-
lication (Shoukry et al. 2003). Together, the temporal kinetic as-
sociations between virus control and T cell immunity and the
altered outcome of reinfection after antibody-mediated T cell
depletion provide strong evidence that adaptive cellular immu-
nity protects against virus persistence (Dahari et al. 2010).
Antibodies and Protective Immunity
Cell culture assays to measure antibody neutralization of HCV
were not available until approximately 15 years after the discov-
ery of HCV. The chimpanzee model was therefore important in
early analyses of humoral immune responses. Co-incubation of
HCV with serum from a chronically infected patient prior to
transfer to a chimpanzee prevented infection, providing the first
evidence of antibody-mediated HCV neutralization (Farci et al.
1994). Passive immunization of a chimpanzee with a neutralizing
monoclonal antibody before HCV challenge was also shown to
prevent apparent infection (Morin et al. 2012). Sterilizing immu-
nity mediated by neutralizing antibodies may offer limited pro-
tection, however. In one recent study, a chimpanzee was
passively immunized with broadly neutralizing serum antibodies
from a patient with a persistent genotype 1a HCV infection
(Bukh et al. 2015). Challenge of the chimpanzee with a mixture of
genotype 1a, 4a, 5a, and 6a HCV isolates that were readily neu-
tralized in cell culture assays resulted in infection. There was no
apparent control of the heterologous HCV genotypes (Bukh et al.
2015), highlighting the challenge of inducing broadly protective
sterilizing immunity by vaccination. Prolonged suppression of
the homologous genotype 1a virus was observed (Bukh et al.
2015), suggesting that antibodies may contribute to control of an
established infection. This result confirmed early observations
that transfer of polyclonal (Krawczynski et al. 1996) or monoclo-
nal (Morin et al. 2012) anti-HCV antibodies after challenge de-
layed but did not prevent the onset of virus replication in some
chimpanzees. The observations also provided direct support for
observations from human studies, where rapid development of
neutralizing antibodies was associated with reduced virus repli-
cation and resolution of acute infection (Dowd et al. 2009;
Lavillette et al. 2005; Osburn et al. 2014; Pestka et al. 2007).
Preventing HCV Infection by Vaccination
Many different experimental HCV vaccines elicited humoral and/
or cellular immunity when assessed for immunogenicity in ro-
dents (Liang 2013). Very few of the vaccines were assessed for
protection of chimpanzees from infection (Liang 2013). The vac-
cines differed in design, reflecting uncertainty about the relative
contribution of antibodies versus T cells to protection from persis-
tence. For instance, vaccines to elicit antibodies against the HCV
envelope proteins E1 and E2 (Houghton 2011; Puig et al. 2004) and
T cells against nonstructural proteins (Folgori et al. 2006) have
been assessed in chimpanzees, as have multi-component vac-
cines designed to elicit humoral and cellular responses
(Elmowalid et al. 2007; Rollier et al. 2004). All these vaccines pro-
tected at least some chimpanzees from HCV persistence. Two
vaccines designed to elicit neutralizing antibody or T cell re-
sponses have advanced to human clinical trials.
Vaccination to Prime Neutralizing Antibodies
An antibody vaccine developed by Michael Houghton and his
colleagues is comprised of recombinant envelope glycopro-
teins E1 and E2 in a microfluidized oil:water emulsion adju-
vant (Houghton 2011). It elicited pan-genotypic neutralizing
antibodies and provided sterilizing immunity in a subset of
vaccinated animals (Meunier et al. 2011). Breakthrough infec-
tions were observed in other animals, but they were more
likely to resolve than infections in mock vaccinated controls
(Houghton 2011). It remains uncertain if protection from persis-
tence was mediated by antibodies or the strong CD4+ T cell
response that this vaccine is known to induce. Based on these re-
sults in the chimpanzee model, the E1/E2 vaccine was assessed
for immunogenicity in humans at low risk for exposure to HCV.
Vaccination generated neutralizing antibodies (Law et al. 2013)
and strong HCV-specific CD4+ T cell responses (Frey et al. 2010)
similar to those detected in immunized chimpanzees. Efforts to
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refine this vaccine approach are underway by Houghton and col-
leagues. Future human trials are likely and could advance the
concept that vaccines eliciting antibodies can alter the course of
HCV infection.
Vaccination to Prime T Cells
The novel hypothesis that vaccination to prime T cell immunity
might be sufficient to prevent HCV persistence has been advanced
by Folgori, Nicosia, and colleagues at Okairos Corporation (now
Glaxo Smith Kline). Chimpanzees immunized with adenovirus
and plasmid DNA vectors encoding nonstructural proteins NS3 to
NS5b developed robust memory CD4+ and CD8+ T cell immunity
(Folgori et al. 2006). Upon challenge with HCV, the vaccine-
primed T cell response was rapidly recalled and was associated
with profound suppression of acute phase viremia (Folgori et al.
2006). Rechallenge studies in chimpanzees supported the concept
that the T cell response alone could be protective. Chimpanzees
with a T cell response but no detectable neutralizing antibody fol-
lowing viral clearance from the initial infection were protected
against rechallenge (Bukh et al. 2008). Human subjects primed
and boosted with a similar vaccine comprised of two serologically
distinct adenovirus vectors elicited similar T cell responses
against nonstructural HCV proteins (Barnes et al. 2012). Further
refinement by boosting with a modified vaccinia virus Ankara
vector elicited stronger, multifunctional T cells that targeted epi-
topes conserved in many HCV genotypes (Swadling et al. 2014).
The ability of this vaccine to protect against HCV persistence is
being assessed in subjects at risk for infection because of injection
drug use (Clinical Trials.gov NCT01436357).
The chimpanzee model of HCV infection has provided critical
support for the concept that a protective HCV vaccine is feasible
and that the goal of vaccination should be prevention of persis-
tence and not sterilizing immunity. In the absence of clear surro-
gate markers of immune protection that existed for other
hepatotropic viruses, the model also provided proof that candi-
date HCV vaccines reduced and did not increase the risk of persis-
tent infection before human clinical trials were undertaken. The
study of antiviral immunity and vaccine-mediated protection
have established an important legacy for chimpanzee research as
efforts to reduce the global burden of HCV infection continue.
The Path to a Cure for HCV and ramifications
for HBV Co-infections
The Challenge of Resistance to HCV Antivirals
With the development of the replicon model (Lohmann et al.
1999), the tools were available for high throughput drug screen-
ing, and many pharmaceutical and biotech companies were
placing major resources into this effort. The period between
2000 and 2014 was an era of intense drug discovery, preclinical
testing in chimpanzees, and clinical trials in humans. During
this same period, scientists were using the same tools to pro-
vide a greater understanding of the functions for HCV proteins
(reviewed in Liang 2009; Lindenbach and Rice 2005; Scheel and
Rice 2013; Tellinghuisen et al. 2007). Despite the rapid pace of
scientific discovery, the development of a curative therapy was
a daunting challenge. Infected individuals produce approxi-
mately one trillion virions per day with a substantial genomic
diversity due to error-prone replication. Mutations preexist that
could provide resistance to any single or double antiviral ther-
apy. Eventually, four antiviral targets would be selected as the
finalists for further drug development, although others contin-
ued to be pursued. The most actively pursued targets would be
the NS3 protease, NS5A, non-nucleoside inhibitors of the NS5B
RNA polymerase, and nucleos(t)ide analogues that inhibited
RNA replication (Gotte and Feld 2016). The proof of concept for
each class of antiviral was demonstrated in the chimpanzee,
and examples of these antivirals will be discussed here. The
best of the antiviral drugs could reduce the level of virus by
10,000-fold in just 3 days. However, resistance to these drugs
developed immediately, literally in days. The virus levels in the
blood declined rapidly just to rebound due to expansion of virus
with genetic mutations for resistance. There were initial con-
cerns that therapies would create populations of patients resis-
tant to all of the drugs. This led to research on alternative
targets that promised lower probability of resistance and among
these was the miR122 inhibitor, Miravirsen (Lanford et al. 2010).
However, with the use of cocktails of selected drugs, it soon
became clear that infection in chimpanzees and humans could
be cured by cocktails of two to four direct-acting antivirals.
Antiviral Efficacy Studies in Chimpanzees Lead the Path
to a Cure
Early studies in chimpanzees demonstrated the high potency of
direct-acting antivirals, while at the same time providing the first
glimpse of how rapidly resistance could occur in vivo. A ben-
zothiadiazine nonnucleoside inhibitor of the NS5B RNA polymer-
ase (A-83,7093) reduced viremia by 2.5 logs within 2 days of oral
dosing, but resistant virus was detected almost immediately
while the animals were still on therapy (Chen et al. 2007).
Resistance mutations could be detected on day 2 with 67% of the
virus containing at least one resistance mutation, which
increased to 87% by day 5. More troubling was the persistence of
mutations after cessation of therapy. The rapid emergence of
resistant viruses during viral decline suggests that these muta-
tions not only preexist in the quasispecies, but exist as replication
complexes in hepatocytes and are the primary source of viral pro-
duction early after antiviral treatment when the decline of WT
from the circulation correlates with the half-life of viral clearance.
The potency of NS3 protease inhibitors was examined in chim-
panzees with numerous compounds. One particular example
highlighted both the rapid development of resistance and the
generation of unfit mutants that did not persist in the absence of
selective pressure from the drug. EA-058 was orally dosed for only
2.5 days and reduced the viral load by 4-log10 (Pilot-Matias et al.
2009). Sequencing of virus on day 4, the nadir for viral load, re-
vealed that 80% of viral genomes contained resistance mutations.
However, the mutations clearly reduced the fitness for replica-
tion, since only WT sequence could be detected after a few days
in the absence of drug. Low fitness mutants probably do not rep-
resent a hurdle to retreatment of people that fail therapy, but pro-
longed dosing may provide an opportunity for compensatory
mutations that restore fitness to the resistant virus.
One of the early studies of critical importance in this context
evaluated a highly potent nucleoside analogue in chimpanzees
(Carroll et al. 2009). MK-608 resulted in suppression of HCV
below the limits of detection during 37 days of therapy, and
virus remained undetectable for 12 days after cessation of ther-
apy. One conclusion from this study is that resistant mutants
of nucleoside analogues were highly unfit and persisted below
the limit of detection. The first evidence of the potential for a
cure came from experiments conducted with a combination of
MK-608 (nucleoside analogue) and MK-7009 (NS3 protease
inhibitor) (Olsen et al. 2011). Double therapy was conducted for
37 days with extension of dosing the protease inhibitor for a
total of 84 days. One of three chimpanzees developed
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resistance during monotherapy 28 days after stopping the
nucleoside analogue. The second chimpanzee rebounded 21
days after discontinuation of both drugs. One chimpanzee ex-
hibited a sustained viral response at 6 months after therapy
with no detectable virus and by definition was cured of HCV.
Although the group size was small and only one animal was
cured, this provided proof that an HCV cure could be attained
with as few as two potent antivirals.
The concerns over resistance led to evaluation of other targets
for therapy including host factors required by HCV for replication.
One particularly attractive target was miR-122, a highly abundant,
liver-specific microRNA. HCV has two binding sites for miR-122 in
the 5′ noncoding region of the RNA genome, and both are essen-
tial for maintaining RNA abundance (Jangra et al. 2010; Jopling
et al. 2008; Masaki et al. 2015). The drug SPC3649 or Miravirsen is
an antisense oligonucleotide that targets miR122. This drug is the
first example of a DNA-based therapy that is highly efficacious
when administered systemically, and the success of the drug re-
lies on the use of the Locked Nucleic Acid technology that pro-
vides enhanced stability and higher binding affinity for the
oligonucleotide. In contrast to direct-acting antivirals, Miravirsen
resulted in a slow decline of virus over weeks rather than days,
but no resistance developed with extended dosing. Miravirsen
was administered once per week for 12 weeks and induced a 2.6-
log drop in viral RNA levels that persisted for months after the
last dose of drug (Lanford et al. 2010). The slow decline of virus
is due to the need to load the liver with the antisense and
completely sequester miR-122, while the stability of the antisense
in the liver maintained antiviral activity for extended periods.
The drug provided an extremely high genetic barrier to resistance.
No adaptive or antiviral resistant mutations were detected in the
5′ NCR. Although Miravirsen progressed to phase II human trials,
the need for antivirals that targeted host factors was reduced by
the rapid development and FDA approval of curative cocktails of
direct-acting antivirals. The antivirals such as Miravirsen may still
play essential roles in treatment of some individuals if resistance
to DAA cocktails proves significant in the future.
In 2014, the FDA announced the approval of the first
interferon-sparing all-DAA combination regimen for HCV.
Harvoni is a combination of a nucleoside analogue and an NS5A
inhibitor. By 2016, three additional cocktails were approved:
VIEKIRA XR, Zepatier, and Epclusa. All these cocktails provide a
>95% cure rate with a once-per-day dosing over 12 weeks and
minimal side effects. This represents the first cure of a chronic
viral disease and represents the cumulative efforts of thousands
of scientists over 40 years, since the description of NANBH. Most
importantly, these therapies would not be available today without
the important contribution of the chimpanzee model, from the
discovery of HCV to the development of the cure.
Hepatitis B Virus Reactivation after HCV Cure
Unexpectedly, in October of 2016, the FDA released a drug-safety
communication warning of the risk of hepatitis B reactivation in
some patients treated with HCV direct-acting antivirals. This
communication included an FDA Boxed Warning, the highest of
the FDA warnings, for all of the direct-acting antivirals for HCV,
including the approved cocktails. At the time of the warning, the
FDA had received reports of 24 cases, including one that required
a transplant and two that resulted in death. The mechanism of
HBV reactivation is not understood. Presumably, HCV chronic
infection suppresses HBV, and the cure of the infection can lead
to reactivation of HBV replication and disease. The most likely
mechanisms would involve the immune response to HCV. The
high level of innate immune response to HCV in the liver, as
discussed above, may have an impact on HBV suppression.
Reactivation of HBV during therapeutic immune suppression
and chemotherapy are well documented and can lead to lethal
outcomes. The American Association for the Study of Liver
Disease conducted a survey that provided information on 188
patients with HBV reactivation during chemotherapy; 57%
required hospitalization, 37% required intensive care, and 23%
died. These patients were reactivations during chemotherapy,
not following HCV cure. Sufficient data are not available to
determine the outcome of HBV reactivation following HCV
cure. Clearly, HBV reactivation will continue to be a problem in
many areas of medical care, but the inclusion of HCV cure as
one of them was unexpected.
Immune Status Following HCV Cure from Antiviral
Therapy
It is uncertain if immune responses recover in cured indivi-
duals or provide protection against reinfection. This concept
has been tested in one chimpanzee cured of chronic infection
with DAA (Callendret et al. 2014). CD8+ T cells visualized in
liver during chronic infection were still present in liver 2 years
after termination of virus replication by DAA therapy.
Rechallenge resulted in rapid expansion of some HCV-specific
T cells (Callendret et al. 2014). However, they provided only
transient control of HCV replication, and a second persistent
infection was established when the virus rapidly acquired
escape mutations in class I epitopes (Callendret et al. 2014).
This important study serves as a starting point for detailed
studies of immune reconstitution and protection in humans at
risk of HCV exposure after successful DAA treatment.
Novel Therapeutics for HBV
The HBV vaccine developed in chimpanzees in the 1980s is
used worldwide and has resulted in a generation of immune in-
dividuals where fully implemented. However, this is of little
benefit to the 350 million people chronically infected with HBV
and at high risk of end-stage liver disease and liver cancer.
Nucleos(t)ide analogue therapies are highly effective at sup-
pressing viral replication and reducing diseas but must be
taken for life. Cure of HBV infection is not yet possible, but
novel therapeutic approaches are being developed. The chal-
lenge with HBV is the persistence of the highly stable cova-
lently closed circular DNA that is the transcriptional template
for all HBV proteins and the pregenomic RNA (Seeger and
Mason 2015). This DNA is nonreplicating and is present in the
nucleus of nondividing hepatocytes, providing remarkable per-
sistence even in individuals that have apparently resolved
infection, as discussed above under reactivation of HBV infec-
tion. The chimpanzee model of HBV infection has been essen-
tial to our understanding of this disease. An adequate review of
this literature is not possible in this chapter, but several com-
prehensive reviews are available (Chisari et al. 2010; Guidotti
et al. 2015; Wieland 2015).
This section will describe two novel approaches that were
among the last tested in chimpanzees prior to the ban of
research and both subsequently moved to human trials. The
first is an immune modulator that is an agonist for Toll-Like
Receptor 7 (TLR7) and the second is a novel small interfering
RNA (RNAi) that targets HBsAg as an immune modulation
approach. TLR7 is a receptor present on various immune cells
including plasmacytoid dendritic cells and B cells that when
ILAR Journal, 2017, Vol. 58, No. 2 | 179
stimulated activates the innate immune response and aides in
orchestration of the adaptive immune response. GS-9620 is an
orally available TLR7 agonist that was tested in HBV chronically
infected chimpanzees (Lanford et al. 2013). Two rounds of
4 weeks of therapy provided potent activation of innate immune
response followed by a T cell response. The viral load declined
by 100-fold, and remarkably the reduction in virus persisted for
many months after cessation of therapy, suggesting that the
immune status of the animals had been altered (Figure 2).
Evaluation of the liver for cells expressing HBV core antigen
revealed a dramatic drop in the number of positive cells during
therapy. This same drug has shown promise in rhesus maca-
ques (Macaca mulatta) infected with SIV. In some animals treated
with HIV antiviral therapy and then given GS-9620, virus did not
rebound after stopping therapy. GS-9620 is in clinical trials as a
candidate for reducing HIV-latent viral reservoirs.
ARC-520 is an RNAi antiviral that targets HBV transcripts and
includes technology to target the liver and release the small
interfering RNA from the endosomal compartment without deg-
radation (Wooddell et al. 2013). The RNAi triggers the degradation
of all HBV transcripts including surface antigen (HBsAg). One of
the concepts behind this therapy is the prevailing hypothesis
that HBsAg suppresses the immune response and thus supports
persistence of the virus. A study in HBV chronically infected
chimpanzees was designed for ARC-520 in combination with
nucleoside therapy to reflect patients that would likely be on
nucleoside therapy prior to use of ARC-520. As expected, nucleo-
side monotherapy as a lead-in had little effect on HBsAg, but
reduced viremia by multiple logs. In contrast, initiation of ARC-
520 provided profound reduction in HBsAg, with a maximum
reduction of more than 2 logs of HBsAg (Figure 3) (Wooddell et al.
2017). ARC-520 provided greater reduction of HBsAg in HBeAg
positive chimpanzees compared to HBeAg negative chimpan-
zees. During the course of these studies, it was determined that
substantial HBsAg is derived from integrated HBV DNA, rather
than cccDNA. This observation accounted for the lower percent
reduction of HBsAg in HBeAg negative animals. As predicted, re-
positioning of the small interfering RNA target sequences to
effectively eliminate transcripts from integrated DNA dramati-
cally increased the percent reduction of HBsAg in HBeAg negative
chimpanzees (Wooddell et al. 2017). This highly promising tech-
nology progressed to human clinical trials.
NHP Studies of Hepatitis A
Hepatitis A is an acute inflammatory disease of the liver. It is
an ancient disease with worldwide distribution. The causative
agent, HAV, is an atypical member of the Picornaviridae, a large
and diverse family of positive-strand RNA viruses (Ehrenfeld
et al. 2010). NHPs have figured prominently in the history of
HAV research, contributing in three distinct areas of research:
characterization of virologic and immunologic features of infec-
tion, development of efficacious HAV vaccines, and (more
recently) demonstration of the unusual dual lifestyle of HAV as
both a naked, nonenveloped virus and a membrane-cloaked,
quasi-enveloped virion (Feng et al. 2014).
Human HAV represents the type species of the genus
Hepatovirus, a genus that has recently been shown to include
multiple viruses infecting a variety of small mammals, including
bats, rodents, shrews, and hedgehogs (Drexler et al. 2015). It differs
substantially in sequence and structure from other mammalian
picornaviruses, with its capsid structure sharing features common
to primitive, picornavirus-like insect viruses (Wang et al. 2015).
Human HAV is capable of infecting a variety of Old World and
New World NHPs, including chimpanzees (Dienstag et al. 1975;
Maynard et al. 1975a), rhesus and cynomolgus macaques (Macaca
fascicularis) (Amado et al. 2010; Shevtsova et al. 1988), green mon-
keys (Cercopithecus aethiops) (Shevtsova et al. 1988), marmosets and
tamarins (Saguinus mystax and S. labiatus) (Maynard et al. 1975b;
Provost et al. 1978), and owl monkeys (Aotus trivirgatus) (Lemon
et al. 1982). Viruses have been recovered from naturally infected
NHPs held in captivity, and two-way transmission of virus
between captive NHPs and their handlers was common prior to
the availability of effective vaccines (Dienstag et al. 1976a). An
Figure 3 Decline in serum HBsAg levels in chimpanzees chronically infected
with HBV during therapy with ARC-520. ARC-520 is an RNAi antiviral that tar-
gets HBV transcripts. The RNAi triggers the degradation of all HBV transcripts
including surface antigen (HBsAg). Four chimpanzees positive (HBeAg+) or neg-
ative (HBeAg−) for serum HBV e-antigen were treated with a lead-in period
with monotherapy of standard of care nucleoside analogues (days −57 to 0).
This therapy had minimal impact on HBsAg but reduced serum HBV DNA levels
by multiple logs (data not shown). Initiation of ARC-520 therapy resulted in
rapid decline in HBsAg levels, with up to a 2-log decline. ARC-520 provided
greater reduction of HBsAg in HBeAg positive chimpanzees compared to HBeAg
negative chimpanzees. Figure derived from data in Wooddell et al. RNAi-based
treatment of chronically infected patients and chimpanzees implicates inte-
grated hepatitis B virus DNA as a source of HBsAg. Sci Transl Med, In press.
Figure 2 TLR7 agonist GS-9620 induces a decrease in HBV DNA in the serum of
a chimpanzee. A chimpanzee chronically infected with HBV was treated with oral
GS-9620 therapy at 1mg/kg or 2mg/kg, with three times per week dosing for four
weeks at each level. The line graph illustrates the decline in viremia as determined
by quantitative PCR (genomes/ml). A maximum of 2.2 log decrease in viremia was
observed, and suppression of HBV persisted for months after discontinuing ther-
apy, suggesting an alteration in the immune response of the chimpanzee to HBV.
Figure modified from Gastroenterology 2013;144(7):1508–1517.
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HAV strain recovered from an African green monkey may repre-
sent a true simian strain, close to human HAV in nucleotide
sequence but with minor differences in antigenic structure and
perhaps species-specific pathogenicity (Arankalle and
Ramakrishnan 2009; Emerson et al. 1996). Almost half a century
has lapsed since the discovery that human HAV can be transmit-
ted experimentally to NHPs. Only recently has it been recognized
that infection is also possible in mice with genetic deficits in
innate immunity (Hirai-Yuki et al. 2016a).
HAV is spread primarily by fecal-oral transmission, and it was
first identified by electronmicroscopy in the feces of experimentally
infected human prisoner volunteers (Feinstone et al. 1973). Prior to
its identification, however, the virus was recognized to infect and
cause disease in tamarin/marmosets (Holmes et al. 1969). A series
of studies in experimentally infected chimpanzees, tamarin/mar-
mosets, and owl monkeys subsequently established the hepato-
tropic nature of HAV (Dienstag et al. 1976b; Keenan et al. 1984;
Lanford et al. 2011; Maynard et al. 1975a; Schaffner et al. 1977;
Schulman et al. 1976). Acute inflammatory liver injury was
found to occur coincident with the appearance of antibodies
to the virus (anti-HAV), typically after a relatively lengthy 2- to
3-week subclinical phase (Figure 4). Fecal shedding of virus and
a low magnitude viremia persist during much of this subclinical
period (Cohen et al. 1989; Taylor et al. 1993). NHPs have been in-
fected by oral as well as intravenous inoculation of virus, with
the required infectious dose of virus 10,000-fold greater when
given orally versus intravenously to chimpanzees or tamarin/
marmosets (Purcell et al. 2002).
Studies in chimpanzees demonstrated large amounts of
virus in bile (Schulman et al. 1976), suggesting that most virus
shed in feces is derived from the liver. Other studies in tama-
rin/marmosets and chimpanzees revealed the presence of viral
antigen within hepatocytes and hepatic Kupffer cells; lesser
amounts were present within germinal centers of the spleen
and lymph nodes and along the glomerular basement mem-
brane in the kidney (Mathiesen et al. 1978; Shimizu et al. 1978).
Extensive efforts to document an enteric site of virus replica-
tion in orally and intravenously infected tamarin/marmosets
and owl monkeys provided generally negative results (Asher
et al. 1995; Mathiesen et al. 1978, 1980). The only evidence for
replication within the gut comes from studies of orally inocu-
lated owl monkeys, in which viral antigen was putatively iden-
tified by immunofluorescence in isolated epithelial cells in
crypts within the small intestine (Asher et al. 1995). Small
amounts of virus have been found within saliva from chimpan-
zees (Cohen et al. 1989), the source of which is uncertain. This
large body of work effectively defined the virologic parameters
of acute HAV infection. The results of experimental infections
in humans done prior to and following World War II, as well as
subsequent observational clinical studies, suggest that HAV
pathogenicity is very similar in humans (Boggs et al. 1970;
Feinstone et al. 1973; Havens 1946; Krugman et al. 1959).
Fulminant hepatitis is a rare complication of infection in hu-
mans and has been observed in a single infected chimpanzee
(Theamboonlers et al. 2012). Importantly, unlike other viruses
that cause acute hepatitis in humans, HAV is not capable of es-
tablishing long-term persistent infections in either humans or
NHPs. However, fecal HAV shedding may persist for up to
5 months in infected infants (Rosenblum et al. 1991).
Studies done over 80 years ago demonstrated that symp-
tomatic infectious hepatitis (presumably hepatitis A) can be
prevented in humans by prophylactic administration of pooled
human serum immune globulin (Gellis et al. 1945). This early
work effectively established the existence of serum anti-HAV
as a strong correlate of immunity. Vaccines in use today are
Salk-style, formalin-inactivated, and alum-adjuvanted vaccines
prepared from virus propagated in cell culture (Fiore et al.
2006). Studies done in tamarin/marmosets by Philip Provost
and Maurice Hilleman at the Merck Laboratories provided early
proof-of-principle for such vaccines by demonstrating the pro-
tective potential of formalin-inactivated virus recovered from
the liver of infected animals (Provost and Hilleman 1978).
Subsequent studies carried out by the US Army confirmed that
a vaccine produced by formalin inactivation of cell culture-
derived virus was capable of protecting owl monkeys against
subsequent, wild-type virus challenge (Binn et al. 1986). An
important step prior to the registration trials of commercially
produced vaccines was the demonstration that serum
Figure 4 Virologic and immunologic events during acute HAV infection in a
chimpanzee inoculated intravenously with wild-type HAV. The bottom panel
shows the presence of viral RNA (GE, genome equivalents) in serum (GE/ml),
feces (GE/gm), and liver tissue (GE/μg total RNA) in relationship to serum ala-
nine aminotransferase (ALT) activity shown in the shaded zone. The prolonged
persistence of intrahepatic HAV RNA is surprising. The panel immediately
above shows total anti-HAV antibody (% blocking in a competitive ELISA assay)
and IgM anti-HAV (ELISA O.D.) The next two panels show frequencies of HAV-
specific CD4+ and CD8+ T cells among peripheral blood mononuclear cells, as
determined in an IFN-γ intracellular staining (ICS) assay. CD8+ cells were also
quantified on the basis of staining with tetramers targeting epitopes in pX, 2B,
and 3Dpol. Note the difference in scale between CD4+ and CD8+ T cell frequen-
cies. The top panel shows type I IFN responses to HAV infection as reflected in
minimal and only early serum IFN-α levels detectable by cytokine ELISA, and
minimal increases in intrahepatic expression of IFN-stimulated genes IFIT1 and
ISG15. pDCs were detected in liver tissue only at 1 week after viral challenge
(arrow). Figure reproduced from Curr Opin Virol 2015 Apr; 11:7–13.
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antibodies from humans immunized by a candidate vaccine
protected against virus challenge in chimpanzees (Purcell et al.
1992). Thus, studies in NHPs provided data that contributed
directly to the development of vaccines that have since pro-
tected millions of persons from HAV infection.
Early studies in NHPs also explored the potential for attenu-
ated hepatitis A vaccines based on the reduced virulence of
virus passaged in cell culture. Patient-derived isolates of HAV
replicate, but only poorly, in a variety of cultured mammalian
cell lines (Binn et al. 1984). HAV was first isolated in cell culture
at Merck following serial passage of virus in tamarin/marmosets
(Provost and Hilleman 1979). With continued passage in cell cul-
ture, the virus adapts and replicates more rapidly and to higher
titer, and in some cases with cytopathic effect (Daemer et al.
1981; Lemon et al. 1991). Cell culture adaptation is associated
with key changes in the nucleotide sequences of the nonstruc-
tural HAV 2B protein and a translational control element, the
internal ribosome entry site located within the 5′ nontranslated
segment of the viral RNA genome (Funkhouser et al. 1994;
Jansen et al. 1988). Passage of the virus in cell culture was
shown to lead to a progressive loss of virulence in chimpanzees,
raising early hopes that such virus might be used for develop-
ment of an attenuated vaccine (Feinstone et al. 1983a; Karron
et al. 1988; Provost et al. 1983). However, these studies also sug-
gested that the reduced virulence of cell culture-passaged virus
was due to a reduced capacity for replication in vivo. This was
confirmed subsequently by poor immunogenicity of an attenu-
ated vaccine candidate in humans (Midthun et al. 1991), result-
ing in the eventual abandonment of this vaccine strategy.
In recent years, studies in experimentally infected NHPs
have provided fresh insight into the nature of the immune
response to HAV and how the virus is cleared from the liver.
Studies done recently in chimpanzees, prior to the NIH morato-
rium on such studies, revealed that acute infection engenders
only paltry intrahepatic innate immune responses (Lanford
et al. 2011). Much less transcriptional activation of interferon-
stimulated genes was observed than in acute, resolving hepati-
tis C virus infection. This lack of a strong interferon response is
likely due to the ability of HAV-encoded proteases to degrade
human MAVS, TRIF, and NEMO, key host proteins involved in
the induction of interferon responses to virus infection (Qu
et al. 2011; Wang et al. 2014; Yang et al. 2007). A weak type-I
interferon response was evident during only the first 2 weeks
of infection in chimpanzees (Figure 4), prior to the onset of liver
injury and peak fecal shedding of virus, and was associated
with transient infiltration of the infected liver by plasmacytoid
dendritic cells (Feng et al. 2015; Lanford et al. 2011).
HAV RNA was found to persist for up to 10 months within
the liver following resolution of biochemical evidence of liver
injury in these chimpanzees (Figure 4) (Lanford et al. 2011).
Whether this RNA reflects the presence of infectious virus in
the liver is uncertain, but it was not associated with persistent
fecal shedding. Declines in intrahepatic viral genome copy
numbers correlated well with the intrahepatic abundance of
multi-functional, virus-specific CD4+ T cells (Zhou et al. 2012).
Such studies cannot be done in human subjects due to the
inability to access acutely infected liver tissue, and they are rel-
evant to our understanding of the immune mechanisms medi-
ating control of other, more pathogenic human hepatitis
viruses. The results of these chimpanzee studies suggest a
novel paradigm for cytokine-mediated CD4+ T cell control of
HAV infection that is distinct from earlier concepts of a primary
role for cytotoxic CD8+ T cell immunity (Walker et al. 2015).
However, B cell responses, which dominate host transcriptional
changes in the acutely HAV-infected liver (Lanford et al. 2011),
and antibody are key to immunity against reinfection.
Finally, the viremia associated with acute HAV infection in
chimpanzees has been shown to be comprised primarily, if not
exclusively, of low-density, membrane-cloaked, quasi-enveloped
virions (Feng et al. 2013). These studies confirmed the biologi-
cal relevance of cell culture studies showing that HAV is
released in a noncytolytic, exosome-like fashion from infected
cells completely cloaked in host-derived membranes. This
unusual mechanism for egress of a classically nonenveloped
virus involves engagement of the host ESCRT-III (endosomal
sorting complex required for transport) complex by fully
assembled capsids (Feng et al. 2013). The quasi-enveloped
virus is resistant to neutralizing antibodies but is neutralized
following its entry into hepatocytes and transport to an endo-
lysosomal compartment, where its membranes are degraded.
Virus shed in feces of infected chimpanzees lack such mem-
branes, presumably because they are removed by the deter-
gent action of bile salts during passage of the virus through
the biliary tract (Feng et al. 2013; Hirai-Yuki et al. 2016b). This
dual lifestyle allows for stealthy spread of membrane-cloaked
virus within the infected host and a high degree of physical
stability of naked, nonenveloped virions promoting environ-
mental transmission between hosts. These studies provide
insight into how a proteinaceous virus capsid can gain egress
across the hydrophobic plasma membrane without cell lysis.
They have blurred the classic distinction between enveloped
and nonenveloped viruses (Feng et al. 2013) and confirm the
continuing importance of NHP models in dissecting patho-
genic mechanisms of human hepatitis viruses.
Hepatocellular Carcinoma in Chimpanzees
Thirty-nine years have passed since the first experimental
transmission of NANBH to chimpanzees (Alter et al. 1978;
Hollinger et al. 1978). The long-term consequences of persistent
infection with HCV and HBV appear to be minimal. With
increasing follow-up and duration of infections, it is clear that
few chimpanzees experience progressive liver disease due to
chronic viral hepatitis. Historically, two chimpanzees with
hepatocellular carcinoma (HCC) were reported at the LEMSIP
facility, but only one of the tumors was subsequently con-
firmed as HCC (Muchmore et al. 1988; Tabor et al. 1994). The
Southwest National Primate Research Center has maintained
viral and pathological surveillance on both infected and unin-
fected chimpanzees for over two decades. Although some ani-
mals exhibit mildly elevated liver enzymes, inflammatory
histological changes and fibrosis are minimal or absent. The
lack of contributing cofactors such as alcohol consumption,
obesity, and high-iron diet may play a role in the mild nature of
the infections in chimpanzees. We previously reported two
additional cases of HCC, one each with persistent HCV and HBV
infections (Lanford et al. 2008). The HCV-infected animal exhib-
ited mild portal fibrosis, but cirrhosis was not present. The
HBV-infected animal had metastatic HCC and advanced cirrho-
sis. Cumulative data from three research facilities and two
sanctuaries now include 10 cases of HCC, only six of which are
associated with chronic hepatitis infection. Considering that
fewer than 100 chimpanzees are persistently infected with HCV
at the various facilities housing infected animals and most
have been infected for less than three decades, it is actually
surprising that this number of HCC cases have been detected.
With the exception of the one HBV case, all of the tumors arose
in the absence of cirrhosis. Although cirrhosis is often
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considered a prerequisite for development of HCV-associated
HCC in humans, recent studies have revealed an increasing
number of human cases of HCC in the absence of cirrhosis (Yeh
et al. 2010). This raises obvious questions of whether HCV pos-
sesses direct oncogenic activity. Interestingly, the first trans-
genic mice expressing HCV proteins developed spontaneous
HCC, one with the entire ORF and one with core protein (Lerat
et al. 2002; Moriya et al. 1998). Nonetheless, HCC in the absence
of hepatitis infection suggests that at least some chimpanzees
may have genetic factors leading to the development of HCC.
Chimp Haven, the IOM Committee, and Closure
The first laboratories dedicated to research with chimpanzees
were funded in 1930 as the Yale Laboratories for Primate
Biology run by Dr. Robert Yerkes (Table 3). NIH began funding
chimpanzee breeding in the United States in 1960 with the cre-
ation of the National Primate Research Centers. This would
bring an end to importation of animals for research as the
breeding colonies became established, and in 1975 the ban on
importation was formalized with the Endangered Species Act.
The use of chimpanzees for research increased with the discov-
ery of AIDS and the causative virus HIV; however, the need for
chimpanzees in HIV research rapidly declined with the devel-
opment of the rhesus macaque model of SIV infection. NIH
began to evaluate whether the current chimpanzee population
would exceed the needs for biomedical research efforts on HCV
and HBV. In 1995, NIH initiated a moratorium on the breeding
of NIH-supported chimpanzees. At the same time, an effort
was initiated to provide long-term care for a portion of the
chimpanzee population in a federally funded sanctuary. Part of
this effort was initiated at one of the research facilities using
chimpanzees, the Southwest Foundation for Biomedical Research,
today known at Texas Biomedical Research Institute and home
of the Southwest National Primate Research Center. The con-
cept was championed by Linda Brent, the head of the behav-
ioral sciences group at Texas Biomed and the eventual founder
and President of Chimp Haven. In 1995, Chimp Haven Inc. was
founded as a nonprofit organization, and four years later, 200
acres in Louisiana was donated to the sanctuary. In 2002,
Congress approved up to $30 million for construction and
chimpanzee care under the Chimpanzee Health Improvement,
Maintenance and Protection Act. The first 31 chimpanzees
arrived in 2005, all animals from Texas Biomed. The Chimp
Haven website (March 2017) reports that over 300 animals have
been taken in and over 200 are still alive on campus. Funding
from the Chimpanzee Act became exhausted by 2013, requiring
that the federal government expand funding for this program.
Following an Insitute of Medicine report on chimpanzees in 2011,
the NIH announced an interim policy to stop funding research in
chimpanzees but allowed for the possibility of a colony of 50 fed-
erally owned chimpanzees for future research needs. The plan
for a colony of 50 animals was never implemented, and in 2016
NIH announced that it would not maintain a reserve colony and
that no invasive research on chimpanzees would be supported.
In 2015, the federal government further restricted research in
chimpanzees when the U.S. Fish and Wildlife ruled that even
chimpanzees born in captivity at research centers were endan-
gered and special permits would be required for use in research.
The final chapter on chimpanzees is still in progress. Several
research facilities maintain a population of chimpanzees that are
retired. NIH estimates that it will be 2026 before all of the ani-
mals can be moved to Chimp Haven based on available space
and the expected attrition from old age. This remains controver-
sial with animal rights advocates requesting expansion of con-
struction of new facilities at Chimp Haven to accelerate the time
frame, while those currently caring for chimpanzees at biomedi-
cal research facilities cite that the movement of geriatric animals
from the environment and caregivers that they have known
since birth is detrimental to the animals. The existing facilities at
research centers are equivalent to those at Chimp Haven with
indoor/outdoor housing, grass-covered playgrounds, and ele-
vated structures for climbing. Due to the nature of the research
centers, they have more extensive medical facilities and larger
behavioral and veterinarian teams to provide care for the ani-
mals, especially aging animals, while Chimp Haven has a few
large wooded enclosures that the chimpanzees get to experience
on a rotation basis. Both types of facilities provide an exceptional
environment for the animals with extensive efforts for enrich-
ment of their lives. An unbiased observer would conclude that
the animals are enjoying their retirement.
General Summary
The advances in research on hepatitis viruses have been
heavily dependent on the chimpanzee model. Today, entire
generations are immune to HAV and HBV due to vaccines
developed in the chimpanzee that are in widespread use glob-
ally. Eradication of these viruses may be possible in the distant
future as the pool of chronically infected individuals continues
to diminish as each new generation achieves higher rates of
vaccination. However, HBV chronic infection currently affects
over 250 million people, with liver cancer being a common out-
come. The loss of the chimpanzee model has stymied develop-
ment of curative therapies for this infection. Future efforts will
depend on the development of improved mouse models and
perhaps new nonhuman primate models. For HCV, due to dec-
ades of research in chimpanzees, antiviral therapies are avail-
able that require a short course of treatment with minimal side
effects and eradicate a virus that has induced progressive liver
disease and resisted immune elimination for decades.
However, treatment of the 170 million chronically infected indi-
viduals is an unrealistic expectation with these therapies. Here
too, the loss of the chimpanzee model has stymied the devel-
opment of vaccines. Human vaccine trials will be lengthy, as
numerous candidate vaccines will need evaluation, and will be
difficult to coordinate within high risk populations. The use of
other species of nonhuman primates can provide essential
information on novel vaccine strategies, even though efficacy
cannot be evaluated in species other than the chimpanzee.
Future generations will certainly look favorably upon the con-
tribution of the chimpanzee to human healthcare as the
Table 3 History of NIH Chimpanzees
1930 Yerkes starts Yale Laboratories for Primate Biology
1960 NIH NPRCs founded and include chimpanzee breeding
1975 End of importation and implementation of CITES
1986 Increased breeding for HIV vaccine development
1995 NIH moratorium on breeding
1995 Chimp Haven Inc. created as non-profit org
2002 Congress funds CHIMP Act—Federal Sanctuary
2011 Institute of Medicine review of need for chimpanzees
2011 NIH initial halt on research in chimpanzees
2015 Fish & Wildlife designates captive chimpanzees as endangered
2016 NIH projects that all chimpanzees will be in federal sanctuary
by 2026
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positive impact of the vaccines and therapies developed in the
chimpanzee becomes increasingly apparent with time.
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